Compare VHC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | BMEA |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 90.5M |
| IPO Year | 2008 | 2021 |
| Metric | VHC | BMEA |
|---|---|---|
| Price | $14.05 | $1.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $8.71 |
| AVG Volume (30 Days) | 8.9K | ★ 1.1M |
| Earning Date | 03-24-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.99 | ★ 69.19 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $162,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3140.00 | N/A |
| 52 Week Low | $6.60 | $0.87 |
| 52 Week High | $29.00 | $3.07 |
| Indicator | VHC | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 41.41 | 51.19 |
| Support Level | $12.88 | $1.22 |
| Resistance Level | $18.36 | $1.47 |
| Average True Range (ATR) | 1.41 | 0.11 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 16.95 | 50.56 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.